Improving Access to Therapy for Patients With Inborn Errors of Immunity: A Call to Action.
| Autor: | Dorsey MJ; Division of Pediatric Allergy, Immunology & Bone Marrow Transplantation, UCSF Benioff Children's Hospital, University of California, San Francisco, Calif., Condino-Neto A; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil. Electronic address: condino@usp.br. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2023 Jun; Vol. 11 (6), pp. 1698-1702. Date of Electronic Publication: 2023 Apr 28. |
| DOI: | 10.1016/j.jaip.2023.04.019 |
| Abstrakt: | Breakthroughs in sequencing technology, targeted immunotherapy, and immune reconstituting treatment have increased the pool of patients with inborn errors of immunity, requiring expertise from clinical immunologists. A growing category of immunodeficiency, presenting as primary immune regulatory disorder and secondary immunodeficiency due to targeted immune therapy for cancer and autoimmunity, has added to the growing burden of patients needing access to immune-supportive therapy. The confluence of a growing population of patients needing a clinical immunologist, complex payer structures, and inadequate health care representation will exacerbate current problems with access to therapy. Patients, health care providers, researchers, public and private payers, and industry must come together to find solutions to improve access to therapy. In this article, we reviewed the major topics regarding access to therapy for patients with immunodeficiency. (Copyright © 2023. Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|